ArticleBritish journal of cancer2026
A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegorafenib (REG) monotherapy and trifluridine/tipiracil (FTD/TPI), with or without bevacizumab (BEV), are standard later-line treatments for metastatic colorectal cancer (mCRC). However, the optimal treatment sequence remains uncertain.
methodsThe OSERO study was a prospective observational study in patients with mCRC scheduled for later-line treatment with REG or FTD/TPI, with or without BEV (UMIN000040586). Patients were categorized into REG (A), FTD/TPI (B), and FTD/TPI plus BEV (C). The primary endpoint was overall survival (OS). To adjust for imbalances in baseline characteristics, stabilized inverse probability of treatment weights (IPTWs) derived from a propensity score model were applied.
resultsAmong 468 patients, (A, n = 154; B, n = 82; C, n = 232), scheduled second-line treatment rates were 65.6%, 37.8%, and 62.9%. Median overall survival (mOS) was 12.2, 7.5, and 10.6 months, respectively. After IPTW adjustment, mOS was 12.2 (A) and 10.6 months (C) (hazard ratio, 1.03; 95% confidence interval, 0.81-1.30; P = 0.837). Grade ≥ 3 adverse events ( > 10%) included hand-foot syndrome, proteinuria, and hypertension in (A), and neutropenia and anemia (B, C).
conclusionSequential treatment with REGO and FTD/TPI plus BEV therapy yielded comparable survival, suggesting that treatment selection may depend on safety profiles of each drug.
Identifiers
42811047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.